Profile data is unavailable for this security.
About the company
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
- Revenue in USD (TTM)0.00
- Net income in USD-126.22m
- Incorporated2017
- Employees92.00
- LocationNuvalent IncOne Broadway, 14th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 357-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.nuvalent.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.94bn | 557.00 | -- | 6.18 | -- | 3,312.22 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Insmed Inc | 305.21m | -749.57m | 4.06bn | 912.00 | -- | -- | -- | 13.29 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
10X Genomics Inc | 618.73m | -255.10m | 4.40bn | 1.26k | -- | 5.93 | -- | 7.11 | -2.18 | -2.18 | 5.28 | 6.22 | 0.6206 | 2.70 | 5.65 | 491,443.20 | -25.59 | -25.52 | -29.39 | -29.05 | 66.15 | 75.88 | -41.23 | -48.53 | 4.11 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
Alkermes Plc | 1.66bn | 519.16m | 4.55bn | 2.10k | 9.02 | 3.78 | 7.66 | 2.74 | 3.02 | 2.07 | 9.79 | 7.20 | 0.8114 | 1.38 | 5.28 | 792,097.60 | 25.32 | 1.34 | 33.69 | 1.74 | 84.79 | 83.32 | 31.21 | 2.12 | 2.50 | -- | 0.1947 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Biohaven Ltd | 0.00 | -408.17m | 4.66bn | 239.00 | -- | 10.81 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
Organon & Co | 6.26bn | 1.02bn | 4.72bn | 10.00k | 4.62 | -- | 3.75 | 0.7531 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Immunovant Inc | 0.00 | -243.45m | 4.72bn | 164.00 | -- | 6.95 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
Nuvalent Inc | 0.00 | -126.22m | 4.91bn | 92.00 | -- | 7.01 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Krystal Biotech Inc | 50.70m | 10.93m | 5.01bn | 229.00 | 2,002.49 | 6.43 | 297.18 | 98.89 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 5.17bn | 373.00 | 19.31 | 61.61 | 14.22 | 6.24 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Revolution Medicines Inc | 11.58m | -436.37m | 5.22bn | 378.00 | -- | 2.86 | -- | 451.12 | -3.77 | -3.77 | 0.1024 | 11.09 | 0.0081 | -- | 3.91 | 30,634.92 | -30.37 | -29.76 | -32.71 | -32.59 | -- | -- | -3,768.28 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 5.34bn | 376.00 | -- | 12.69 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
BridgeBio Pharma Inc | 9.30m | -643.20m | 5.67bn | 550.00 | -- | -- | -- | 609.38 | -3.95 | -3.95 | 0.0572 | -7.73 | 0.0159 | -- | -- | 16,914.54 | -111.72 | -72.44 | -148.01 | -89.72 | 73.71 | 94.41 | -7,021.94 | -1,225.66 | -- | -13.34 | 4.49 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Blueprint Medicines Corp | 249.38m | -506.98m | 5.80bn | 655.00 | -- | 44.38 | -- | 23.27 | -8.37 | -8.37 | 4.12 | 2.14 | 0.2079 | 0.3354 | 6.23 | 380,732.80 | -42.26 | -29.92 | -50.67 | -34.06 | 96.58 | -- | -203.30 | -116.65 | 3.66 | -25.88 | 0.6465 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 8.72m | 15.25% |
Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 3.86m | 6.75% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.26m | 5.71% |
Perceptive Advisors LLCas of 31 Dec 2023 | 2.92m | 5.10% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.04m | 3.57% |
Fairmount Funds Management LLCas of 31 Dec 2023 | 1.92m | 3.37% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.70m | 2.97% |
Commodore Capital LPas of 31 Dec 2023 | 1.33m | 2.33% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.09m | 1.90% |
Wellington Management Co. LLPas of 31 Dec 2023 | 1.01m | 1.77% |